Federico Bolognani

Ironwood Pharmaceuticals (United States) — United States

Nursing · Health Sciences

33h-index3.6kcitations102works0.92yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Clinical Nutrition and Gastroenterology(24), Autism Spectrum Disorder Research(15), Diet and metabolism studies(11), RNA Research and Splicing(9), Electrolyte and hormonal disorders(9)

Publications102 total

Qualitative Research for the Development of Three New Quality of Life and Treatment Impact Questionnaires for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Digestive Diseases and Sciences·2026Open Access
Comment on Nazarloo et al. Oxytocin, Vasopressin and Stress: A Hormetic Perspective. Curr. Issues Mol. Biol. 2025, 47, 632
Current Issues in Molecular Biology·2026· 1 citedOpen Access
Efficacy and Safety of Once-Weekly Apraglutide in Patients with Short Bowel Syndrome and Intestinal Failure: Results from the Phase 3 STARS Study
Intestinal failure.·2025Open Access
Efficacy and safety of apraglutide in short bowel syndrome with intestinal failure and colon–in–continuity: A multicenter, open-label, metabolic balance study
Clinical Nutrition·2024· 8 citedOpen Access
Efficacy and safety of apraglutide once-weekly in patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF): results from the stars study - a global phase 3 double-blind, randomized, placebo-controlled trial
Clinical Nutrition ESPEN·2024· 1 cited
Apraglutide results in reduced Parenteral Support (PS) needs and improved patient reported outcomes in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon-in-Continuity (CiC)
Clinical Nutrition ESPEN·2024
Increased oral intake and improved energy and carbohydrate absorption at 48 weeks with apraglutide in short bowel syndrome with intestinal failure (SBS-IF) and colon-in-continuity (CIC)
Clinical Nutrition ESPEN·2024
Changes in motility and bowel morphology assessed by magnetic resonance imaging (MRI) in short bowel syndrome with intestinal failure (SBS-IF) and colon-in-continuity (CIC) treated with apraglutide
Clinical Nutrition ESPEN·2024
The effect of apraglutide on gastric emptying in healthy individuals: A phase 1 randomized, placebo-controlled, double-blind, single-center trial
Clinical Nutrition ESPEN·2024
Su1946 CHANGES IN BOWEL MORPHOLOGY AND MOTILITY ASSESSED BY MRI IN PATIENTS WITH SHORT BOWEL SYNDROME INTESTINAL FAILURE (SBS-IF) AND COLON-IN-CONTINUITY (CIC) TREATED WITH APRAGLUTIDE
Gastroenterology·2024
Su1949 THE EFFECT OF APRAGLUTIDE ON GASTRIC EMPTYING IN HEALTHY INDIVIDUALS: A PHASE 1 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, SINGLE-CENTER TRIAL
Gastroenterology·2024· 1 cited
Su1948 APRAGLUTIDE TREATMENT IN SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE (SBS-IF) AND COLON-IN-CONTINUITY (CIC) IS ASSOCIATED WITH INCREASED ORAL INTAKE AND IMPROVED ENERGY AND CARBOHYDRATE ABSORPTION AT 48 WEEKS
Gastroenterology·2024
EFFICACY AND SAFETY OF APRAGLUTIDE ONCE-WEEKLY IN PATIENTS WITH SHORT BOWEL SYNDROME AND INTESTINAL FAILURE (SBS-IF): RESULTS FROM THE STARS STUDY - A GLOBAL PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
Gastroenterology·2024
Su1947 PARENTERAL SUPPORT WEANING, CLINICAL BENEFIT AND IMPROVED PATIENT REPORTED OUTCOMES IN SHORT BOWEL SYNDROME INTESTINAL FAILURE (SBS-IF) PATIENTS WITH COLON-IN-CONTINUITY (CIC) TREATED WITH THE LONG-ACTING GLUCAGON-LIKE PEPTIDE-2 (GLP-2) ANALOG APRAGLUTIDE
Gastroenterology·2024
Pharmacokinetics and Tolerability of a Single Dose of Apraglutide, a Novel, Long‐Acting, Synthetic glucagon‐like peptide‐2 Analog With a Unique Pharmacologic Profile, in Individuals With Impaired Renal Function
The Journal of Clinical Pharmacology·2024· 3 citedOpen Access
Once-weekly (QW) apraglutide decreases parenteral support (PS) in short bowel syndrome with intestinal failure (SBS-IF) and colon-in-continuity (CIC)
Clinical Nutrition ESPEN·2023Open Access
Improved wet weight absorption with apraglutide in short bowel syndrome with intestinal failure (SBS-IF) and colon-in-continuity (CIC)
Clinical Nutrition ESPEN·2023
24: Improvement in wet weight absorption after 4 weeks of apraglutide in patients with Short Bowel Syndrome with Intestinal Failure and Colon-in-Continuity
Transplantation·2023
20: Apraglutide, a novel long-acting GLP-2 analog, decreases the need for Parenteral Support in patients with Short Bowel Syndrome with Intestinal Failure and Colon-in-Continuity
Transplantation·2023· 1 cited
Characterization of the Pharmacokinetic and Pharmacodynamic Profile of Apraglutide, a Glucagon-Like Peptide-2 Analog, in Healthy Volunteers
Journal of Pharmacology and Experimental Therapeutics·2023· 7 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Nora I. Perrone‐Bizzozero(17), Céline Bouquet(7), Richard Delorme(7), Alexandru Gaman(7), Isabelle Scheid(7), Marion Leboyer(7), Christian Czech(6), Daniel C. Tanner(6), Manuel Bouvard(5), Josselin Houenou(5), Charles Laidi(5), María G. Castro(4), Anouck Amestoy(4), Marc-Antoine d’Albis(4), Jennifer Boisgontier(4), Elie Toledano(4), Daniel Stone(3), Pedro R. Löwenstein(3), Štefan Holiga(3), Lorraine Murtagh(3)